Macular Telangiectasia Type 2 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Macular Telangiectasia Type 2 Market Outlook

Thelansis’s “Macular Telangiectasia Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Telangiectasia Type 2 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Macular Telangiectasia Type 2 Overview

Macular telangiectasia (MacTel) type 2 is a bilateral retinal disorder of unknown etiology, characterized by distinct alterations in the macular capillary network and neurosensory atrophy. Initially, the disease manifests temporally to the foveal center and may expand to encompass an oval region with approximate dimensions of 6° horizontally and 5° vertically centered on the foveola. The onset of symptoms typically occurs during the fifth or sixth decade of life, and a subset of patients reports a positive family history. Due to limited awareness among both clinicians and patients, MacTel type 2 is often diagnosed belatedly and may be misidentified as age-related macular degeneration in cases involving neovascularization. The prevalence of MacTel type 2 is rare, estimated at approximately 0.10%, with no significant gender or racial predilections. The mean age of onset is approximately 55 years. Notably, up to 45% of individuals with MacTel type 2 also present with comorbid conditions such as diabetes mellitus, obesity, hypertension, or cardiovascular diseases, which, along with smoking, may elevate the risk of clinical manifestation. Clinically, patients often present with unilateral or bilateral progressive blurred vision. Additional symptoms include metamorphopsia and paracentral scotomas, which can be effectively monitored using Amsler grid testing. Currently, there is no well-established treatment for MacTel type 2, though several interventions aim to prevent further vision loss or slow disease progression:

1. Anti-vascular endothelial growth factor (anti-VEGF) injections: These injections inhibit a chemical in the eye that promotes the growth of abnormal blood vessels, thereby reducing swelling, slowing leakage, and potentially improving vision. Anti-VEGF therapy is the standard care for the proliferative phase of MacTel.
2. Revakinagene taroretcel (NT-501): This encapsulated cell therapy has shown potential in slowing the progression of MacTel.
3. Ciliary neurotrophic factor (CNTF): Preliminary results are promising, but further research is needed to establish its efficacy.

Other treatment modalities for MacTel include focal and grid laser photocoagulation, photodynamic therapy (PDT), intravitreal triamcinolone acetonide (IVTA), and subretinal surgery.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: